๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HER2-positive Early Breast Cancer

Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer NCT07593976Phase 21 site๐Ÿ“ Rouen Centre Henri Becquerel ยท Tests: [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites๐Ÿ“ Vienna๐Ÿ“ Baden๐Ÿ“ Dornbirn Austrian Breast & Colorectal Cancer Study Group ยท Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218Phase 31 site๐Ÿ“ Shanghai Shanghai Jiao Tong University School of Medicine ยท Tests: Docetaxel, Pyrotinib, Trastuzumab (Herceptin), Pertuzumab Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer NCT05306041Phase 262 sites๐Ÿ“ Essen๐Ÿ“ Augsburg๐Ÿ“ Berlin GBG Forschungs GmbH ยท Tests: Inavolisib, PHESGO, Endocrine therapy A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer NCT04985266Phase 249 sites๐Ÿ“ Angers๐Ÿ“ Annecy๐Ÿ“ Avignon Royal Marsden NHS Foundation Trust ยท Tests: Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane A Study of the TheraBionic P1 Device in Breast Cancer NCT07218432NA8 sites๐Ÿ“ Clarkston๐Ÿ“ Detroit๐Ÿ“ Farmington Hills Barbara Ann Karmanos Cancer Institute ยท Tests: TheraBionic P1 Device Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer NCT06220214EARLY Phase 11 site๐Ÿ“ Stony Brook Alison Stopeck ยท Tests: CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization NCT07527741n/a10 sites๐Ÿ“ Loznica๐Ÿ“ Poลพarevac๐Ÿ“ Bor Hoffmann-La Roche Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer NCT07340398Phase 21 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Nab paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, SHR-A1811 Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer NCT07531693n/a1 site๐Ÿ“ Erlangen Institut fuer Frauengesundheit Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer NCT05878314n/a1 site๐Ÿ“ Tรผbingen University Hospital Tuebingen RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites๐Ÿ“ Belleville๐Ÿ“ Livingston๐Ÿ“ New Brunswick Mridula George, MD ยท Tests: Abemaciclib, Letrozole Tirzepatide Weight Loss for MRD+ Early Breast Cancer NCT06517212Phase 21 site๐Ÿ“ Dallas Baylor Research Institute ยท Tests: Tirzepatide Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab NCT05760612Phase 31 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Trastuzumab and neratinib, Trastuzumab and Pertuzumab Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635Phase 217 sites๐Ÿ“ Santa Monica๐Ÿ“ Skokie๐Ÿ“ Billings Merck Sharp & Dohme LLC ยท Tests: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Dalpiciclib, Endocrine therapy OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk NCT05333328Phase 42 sites๐Ÿ“ Seoul๐Ÿ“ Seoul Gangnam Severance Hospital ยท Tests: Ovarian function suppression with endocrine treatments Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer NCT04553770Phase 29 sites๐Ÿ“ Fullerton๐Ÿ“ Los Alamitos๐Ÿ“ Los Angeles Jonsson Comprehensive Cancer Center ยท Tests: Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT07057427Phase 31 site๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: Nab paclitaxel, Docetaxel and Carboplatin, Trastuzumab + Pertuzumab Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX NCT06723990n/a1 site๐Ÿ“ Milan European Institute of Oncology ยท Tests: Neoadjuvant standard treatment for HER2+, Adjuvant standard treatment for HER2+ Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer NCT07616427Phase 23 sites๐Ÿ“ Nanjing๐Ÿ“ Hangzhou๐Ÿ“ Ningbo Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase NCT06894173n/a29 sites๐Ÿ“ Aviano๐Ÿ“ Ancona๐Ÿ“ Avellino Fondazione Policlinico Universitario Agostino Gemelli IRCCS Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer NCT07635342Phase 21 site๐Ÿ“ Shijiazhuang Hebei Medical University Fourth Hospital ยท Tests: Pyrotinib Maleate, Trastuzumab (H, 8mg/kg, pegylated liposomal doxorubicin hydrochloride, Cyclophosphamide, Paclitaxel โ€ฆ A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer NCT06001086Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Disitamb Vedotin ,pyrotinib NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites๐Ÿ“ Sankt Gallen๐Ÿ“ Genolier๐Ÿ“ Winterthur Swiss Cancer Institute ยท Tests: Doxycyclin Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial NCT07407920Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Biospecimen Collection, Hormone Therapy, Pembrolizumab, Pertuzumab, Trastuzumab Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy NCT06711068n/a1 site๐Ÿ“ Beijing Shu Wang Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy NCT07400523Phase 34 sites๐Ÿ“ Zhanjiang๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Ribociclib plus aromatase inhibitor, Aromatase inhibitor A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence NCT06492616Phase 3567 sites๐Ÿ“ Daphne๐Ÿ“ Chandler๐Ÿ“ Gilbert Stemline Therapeutics, Inc. ยท Tests: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases NCT06328465NA1 site๐Ÿ“ Milan European Institute of Oncology ยท Tests: Diffusion whole body MRI
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy